Fig. 4. Change in BMI category (healthy, overweight, class I obesity, class II obesity and class III obesity) at baseline and week 104 for in-trial patients.

In the semaglutide group, 12.0% of patients achieved normal weight status at week 104 (from 0% at baseline), compared with 1.2% (from 0% at baseline) for placebo. BMI classes: healthy (BMI <25 kg m⁻²), overweight (25 to <30 kg m⁻²), class I obesity (30 to <35 kg m⁻²), class II obesity (35 to <40 kg m⁻²) and class III obesity (BMI ≥40 kg m⁻²).